Halozyme Therapeutic
(NQ:
HALO
)
63.85
+0.11 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
NASDAQ:HALO is not too expensive for the growth it is showing.
August 29, 2024
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
August 28, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying.
Via
Chartmill
Top 2 Health Care Stocks That May Plunge In August
August 26, 2024
Via
Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
August 20, 2024
Via
Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
August 01, 2024
Via
Benzinga
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
July 22, 2024
There are signs that NASDAQ:HALO may be ready to breakout.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
August 08, 2024
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.
Via
Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
August 08, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
August 06, 2024
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via
Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via
Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
August 05, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
July 18, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing.
Via
Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
July 16, 2024
Via
Benzinga
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
July 15, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
August 04, 2024
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
Via
InvestorPlace
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
July 18, 2024
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late.
Via
InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
Via
Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
NASDAQ:HALO Shows Potential for a Breakout.
July 09, 2024
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
Via
Chartmill
3 Biotech Stocks to Buy Now: Q3 Edition
July 15, 2024
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry.
Via
InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
July 12, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
June 26, 2024
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.